GlobeNewswire Inc.Jul 1, 7:00 AM ETNeutral
Mentioned only as a current board position held by the newly appointed director; no direct business impact or news related to Foghorn is reported.
Foghorn Therapeutics news
$3.520.00%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Foghorn Therapeutics
GlobeNewswire Inc.Apr 9, 7:00 AM ET▲ Positive
Company is advancing multiple clinical and preclinical programs with presentations at a major cancer research conference. FHD-909 is progressing in Phase 1 trials in collaboration with Eli Lilly, and the company is expanding its pipeline with several degrader programs showing promising preclinical data across different cancer types.
Also mentions FHTX
Articles that tag FHTX but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology